Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection

References

• W. Liu, Li, Y., Shaw, K.S., et al. African origin of the malaria parasite Plasmodium vivax. Nat Commun. 2014;5:3346.
   PubMed Web of Science ®Google Scholar
• W. Liu, Li, Y., Learn, G.H., et al. Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature. 2010;467:420–425.
   PubMed Web of Science ®Google Scholar
• Butler NS, Vaughan AM, Harty JT, et al. Whole parasite vaccination approaches for prevention of malaria infection. Trends Immunol. 2012;33:247–254.
   PubMed Web of Science ®Google Scholar
• Vanderberg JP, Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol. 2004;34:991–996.
   PubMed Web of Science ®Google Scholar
• Kebaier C, Voza T, Vanderberg J. Kinetics of mosquito-injected Plasmodium sporozoites in mice: fewer sporozoites are injected into sporozoite-immunized mice. Plos Pathog. 2009;5:e1000399.
   PubMed Web of Science ®Google Scholar
• Sinnis P, Zavala F. The skin: where malaria infection and the host immune response begin. Semin Immunopathol. 2012;3:275–278.
   PubMed Web of Science ®Google Scholar
• Stewart MJ, Nawrot RJ, Schulman S, et al. Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infect Immun. 1986;51:859–864.
   PubMed Web of Science ®Google Scholar
• B. Yilmaz, Portugal, S., Tran, T.M., et al. Gut microbiota elicits a protective immune response against malaria transmission. Cell. 2014;159:1277–1289.
   PubMed Web of Science ®Google Scholar
• Carlisle KM, Halliwell M, Read AE, et al. Estimation of total hepatic blood flow by duplex ultrasound. Gut. 1992;33:92–97.
   PubMed Web of Science ®Google Scholar
• Y. Charoenvit, Mellouk, S., Sedegah, M., et al. Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody. Exp Parasitol. 1995;80:419–429.
   PubMed Web of Science ®Google Scholar
• Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol. 2009;31:492–500.
   PubMed Web of Science ®Google Scholar
• J. A. Stoute, Slaoui, M., Heppner, D.G., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S malaria vaccine evaluation group. N Engl J Med. 1997;336:86–91.
   PubMed Web of Science ®Google Scholar
• J. A. Regules, Cicatelli, S.B., Bennett, J.W., et al. Fractional Third and Fourth Dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis. 2016;214:762–771.
   PubMed Web of Science ®Google Scholar
• A. Olotu, Fegan, G., Wambua, J., et al. Seven-Year Efficacy of RTS,S/AS01 malaria vaccine among young African Children. N Engl J Med. 2016;374:2519–2529.
   PubMed Web of Science ®Google Scholar
• R. A. Seder, Chang, L.J., Enama, M.E., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341(6152):1359–1365.
   PubMed Web of Science ®Google Scholar
• A. S. Ishizuka, Lyke, K.E., DeZure, A., et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22:614–623.
   PubMed Web of Science ®Google Scholar
• M. Roestenberg, McCall, M., Hopman, J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009;361:468–477.
   PubMed Web of Science ®Google Scholar
• P. L. Felgner, Roestenberg, M., Liang, L., et al. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci Rep. 2013;3:3549.
   PubMed Web of Science ®Google Scholar
• M. C. Behet, Foquet, L., van Gemert, G.J., et al. Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar J. 2014;13:136.
   PubMed Web of Science ®Google Scholar
• W. Nahrendorf, Scholzen, A., Bijker, E.M., et al. Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization. J Infect Dis. 2014;210:1981–1990.
   PubMed Web of Science ®Google Scholar
• S. E. Lindner, Swearingen, K.E., Harupa, A., et al. Total and putative surface proteomics of malaria parasite salivary gland sporozoites. Mol Cell Proteomics. 2013;12:1127–1143.
   PubMed Web of Science ®Google Scholar
• Rosenbloom M, Leikin JB, Vogel SN, et al. Biological and chemical agents: a brief synopsis. Am J Ther. 2002;9:5–14.
   PubMedGoogle Scholar
• Minor TE, Allen CI, Tsiatis AA, et al. Human infective dose determinations for oral poliovirus type 1 vaccine in infants. J Clin Microbiol. 1981;13:388–389.
   PubMed Web of Science ®Google Scholar
• Sinnis P, Zavala F. The skin stage of malaria infection: biology and relevance to the malaria vaccine effort. Future Microbiol. 2008;3:275–278.
   PubMed Web of Science ®Google Scholar
• Tse SW, Radtke AJ, Espinosa DA, et al. The chemokine receptor CXCR6 is required for the maintenance of liver memory CD8(+) T cells specific for infectious pathogens. J Infect Dis. 2014;210:1508–1516.
   PubMed Web of Science ®Google Scholar
• Penny MA, Verity, R., Bever, C.A., et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2015;387(10016):367–375.
   Web of Science ®Google Scholar
• Peng K, Goh, Y.S., Siau, A., et al. Breadth of humoral response and antigenic targets of sporozoite-inhibitory antibodies associated with sterile protection induced by controlled human malaria infection. Cell Microbiol. 2016;18(12):1739–1750.
   Web of Science ®Google Scholar
• J. C. Aguiar, Bolton, J., Wanga, J., et al. Discovery of novel plasmodium falciparum pre-erythrocytic antigens for vaccine development. Plos One. 2015;10:e0136109.
   PubMed Web of Science ®Google Scholar
• Kariu T, Ishino T, Yano K, et al. CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol Microbiol. 2006;59:1369–1379.
   PubMed Web of Science ®Google Scholar
• E. S. Bergmann-Leitner, Mease, R.M., De La Vega, P., et al. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. Plos One. 2010;5:e12294.
   PubMed Web of Science ®Google Scholar
• Bergmann-Leitner ES, Legler PM, Savranskaya T, et al. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. Vaccine. 2011;29:5940–5949.
   PubMed Web of Science ®Google Scholar
• A. Dolo, Modiano, D., Doumbo, O., et al. Thrombospondin related adhesive protein (TRAP), a potential malaria vaccine candidate. Parassitologia. 1999;41:425–428.
   PubMedGoogle Scholar
• S. Khusmith, Charoenvit, Y., Kumar, S., et al. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science. 1991;252:715–718.
   PubMed Web of Science ®Google Scholar
• R. Wang, Charoenvit, Y., Corradin, G., et al. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes. J Immunol. 1996;157:4061–4067.
   PubMed Web of Science ®Google Scholar
• K. A. Bojang, Milligan, P.J., Pinder, M., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001;358:1927–1934.
   PubMed Web of Science ®Google Scholar
• K. E. Kester, Cummings, J.F., Ockenhouse, C.F., et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine. 2008;26:2191–2202.
   PubMed Web of Science ®Google Scholar
• K. E. Kester, Heppner, D.G., Moris, P., et al. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naive adults. Vaccine. 2014;32:6683–6691.
   PubMed Web of Science ®Google Scholar
• J. F. Cummings, Spring, M.D., Schwenk, R.J., et al. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine. 2010;28:5135–5144.
   PubMed Web of Science ®Google Scholar
• A. Harupa, Sack, B.K., Lakshmanan, V., et al. SSP3 is a novel Plasmodium yoelii sporozoite surface protein with a role in gliding motility. Infect Immun. 2014;82:4643–4653.
   PubMed Web of Science ®Google Scholar
• K. E. Swearingen, Lindner, S.E., Shi, L., et al. Interrogating the Plasmodium Sporozoite Surface: identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics. Plos Pathog. 2016;12:e1005606.
   PubMed Web of Science ®Google Scholar
• Kwong PD, Mascola JR, Nabel GJ. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med. 2011;1:a007278.
   PubMed Web of Science ®Google Scholar
• M. Bonsignori, Alam, S.M., Liao, H.X., et al. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol. 2012;20:532–539.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Bottomley MJ, D’Oro U, et al. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J Exp Med. 2016;213:469–481.
   PubMed Web of Science ®Google Scholar
• M. G. Joyce, Zhang, B., Ou, L., et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol. 2016;23:811–820.
   PubMed Web of Science ®Google Scholar
• J. C. Aguiar, LaBaer, J., Blair, P.L., et al. High-throughput generation of P. falciparum functional molecules by recombinational cloning. Genome Res. 2004;14:2076–2082.
   PubMed Web of Science ®Google Scholar
• D. N. Sather, Armann, J., Ching, L.K., et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol. 2009;83:757–769.
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Morris L, Burton DR, et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. 2009;15:866–870.
   PubMed Web of Science ®Google Scholar
• Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16:571–576.
   PubMed Web of Science ®Google Scholar
• L. Chen, Do Kwon, Y., Zhou, T., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 2009;326:1123–1127.
   PubMed Web of Science ®Google Scholar
• J. S. McLellan, Pancera, M., Carrico, C., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011;480:336–343.
   PubMed Web of Science ®Google Scholar
• M. Pancera, Zhou, T., Druz, A., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014;514:455–461.
   PubMed Web of Science ®Google Scholar
• R. Derking, Ozorowski, G., Sliepen, K., et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. Plos Pathog. 2015;11:e1004767.
   PubMed Web of Science ®Google Scholar
• J. Gorman, Soto, C., Yang, M.M., et al. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol. 2016;23:81–90.
   PubMed Web of Science ®Google Scholar
• A. Escolano, Steichen, J.M., Dosenovic, P., et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 Antibodies in Ig Knockin mice. Cell. 2016;166(1445–1458):e1412.
   Google Scholar
• D. Sok, Briney, B., Jardine, J.G., et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science. 2016;353:1557–1560.
   PubMed Web of Science ®Google Scholar
• J. M. Steichen, Kulp, D.W., Tokatlian, T., et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity. 2016;45:483–496.
   PubMed Web of Science ®Google Scholar
• J. S. McLellan, Correia, B.E., Chen, M., et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol. 2011;409:853–866.
   PubMed Web of Science ®Google Scholar
• L. Foquet, Hermsen, C.C., van Gemert, G.J., et al. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J Clin Invest. 2013;124(1):140–144..
   Web of Science ®Google Scholar
• Anker R, Zavala F, Pollok BA. VH and VL region structure of antibodies that recognize the (NANP)3 dodecapeptide sequence in the circumsporozoite protein of Plasmodium falciparum. Eur J Immunol. 1990;20:2757–2761.
   PubMed Web of Science ®Google Scholar
• C. Deal, Balazs, A.B., Espinosa, D.A., et al. Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice. Proc Natl Acad Sci U S A. 2014;111:12528–12532.
   PubMed Web of Science ®Google Scholar
• D. A. Espinosa, Gutierrez, G.M., Rojas-López, M., et al. Proteolytic cleavage of the plasmodium falciparum circumsporozoite protein is a target of protective antibodies. J Infect Dis. 2015;212:1111–1119.
   PubMed Web of Science ®Google Scholar
• R. Herrera, Anderson, C., Kumar, K., et al. Reversible conformational change in the plasmodium falciparum circumsporozoite protein masks its adhesion domains. Infect Immun. 2015;83:3771–3780.
   PubMed Web of Science ®Google Scholar
• A. Coppi, Natarajan, R., Pradel, G., et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J Exp Med. 2011;208:341–356.
   PubMed Web of Science ®Google Scholar
• M. B. Doud, Koksal, A.C., Mi, L.Z., et al. Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc Natl Acad Sci U S A. 2012;109:7817–7822.
   PubMed Web of Science ®Google Scholar
• D. Rathore, Nagarkatti, R., Jani, D., et al. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem. 2005;280:20524–20529.
   PubMed Web of Science ®Google Scholar
• Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015;15:51–57.
   PubMed Web of Science ®Google Scholar
• Apostolico Jde S, Lunardelli VA, Coirada FC, et al. Adjuvants: classification, Modus Operandi, and Licensing. J Immunol Res. 2016;2016:1459394.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Kool M, Willart MA, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009;21:23–29.
   PubMed Web of Science ®Google Scholar
• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287–293.
   PubMed Web of Science ®Google Scholar
• S. T. Agnandji, Agnandji, S.T., Lell, B., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284–2295.
   PubMed Web of Science ®Google Scholar
• Mata E, Salvador A, Igartua M, et al. Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research. Biomed Res Int. 2013;2013:282913.
   PubMed Web of Science ®Google Scholar
• J. A. Lopez, Weilenman, C., Audran, R., et al. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur J Immunol. 2001;31:1989–1998.
   PubMed Web of Science ®Google Scholar
• A. L. Gregson, Oliveira, G., Othoro, C., et al. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. Plos One. 2008;3:e1556.
   PubMed Web of Science ®Google Scholar
• M. Walther, Dunachie, S., Keating, S., et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine. 2005;23:857–864.
   PubMed Web of Science ®Google Scholar
• B. Genton, D’Acremont, V., Lurati-Ruiz, F., et al. Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum. Vaccine. 2010;28:6573–6580.
   PubMed Web of Science ®Google Scholar
• D. M. Gordon, McGovern, T.W., Krzych, U., et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis. 1995;171:1576–1585.
   PubMed Web of Science ®Google Scholar
• A. M. Didierlaurent, Laupèze, B., Di Pasquale, A., et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2016;16(1):1–9.
   Web of Science ®Google Scholar
• R. Audran, Lurati-Ruiz, F., Genton, B., et al. The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial. Plos One. 2009;4:e7304.
   PubMed Web of Science ®Google Scholar
• D. Duffy, Rouilly, V., Libri, V., et al. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity. 2014;40:436–450.
   PubMed Web of Science ®Google Scholar
• S. M. Blaauboer, Mansouri, S., Tucker, H.R., et al. The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo. Elife. 2015;4.
   PubMed Web of Science ®Google Scholar
• F. Qian, Guo, A., Li, M., et al. Salmonella flagellin is a potent carrier-adjuvant for peptide conjugate to induce peptide-specific antibody response in mice. Vaccine. 2015;33:2038–2044.
   PubMed Web of Science ®Google Scholar
• S. Apostolico Jde, Boscardin, S. B., Yamamoto, M. M., et al. HIV envelope trimer specific immune response is influenced by different adjuvant formulations and heterologous prime-boost. Plos One. 2016;11:e0145637.
   PubMed Web of Science ®Google Scholar
• Ciocca L, Mazzoni S, Marchetti C, et al. The concept of prosthetically guided maxillofacial and implant surgery for maxillary reconstruction. J Oral Implantol. 2016;42:184–188.
   PubMed Web of Science ®Google Scholar
• N. Khan, Vidyarthi, A., Pahari, S., et al. Signaling through NOD-2 and TLR-4 Bolsters the T cell priming capability of dendritic cells by inducing autophagy. Sci Rep. 2016;6:19084.
   PubMed Web of Science ®Google Scholar
• M. Samo, Choudhary, N.R., Riebe, K.J., et al. Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface. Vaccine. 2016;34:1193–1200.
   PubMed Web of Science ®Google Scholar
• L. J. Thompson, Lai, J.F., Valladao, A.C., et al. Conditioning of naive CD4(+) T cells for enhanced peripheral Foxp3 induction by nonspecific bystander inflammation. Nat Immunol. 2016;17:297–303.
   PubMed Web of Science ®Google Scholar
• Steel RW, Sack BK, Tsuji M, et al. An opsonic phagocytosis assay for Plasmodium falciparum sporozoites. Clin Vaccine Immunol. 2017 Feb 6;24(2). pii: e00445-16. doi:10.1128/CVI.00445-16.
   Google Scholar
• Carey AF, Menard R, Bargieri DY. Scoring sporozoite motility. Methods Mol Biol. 2013;923:371–383.
   PubMedGoogle Scholar
• D. E. Neafsey, Juraska, M., Bedford, T., et al. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med. 2015;373:2025–2037.
   PubMed Web of Science ®Google Scholar
• Hollingdale MR, Nardin EH, Tharavanij S, et al. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol. 1984;132:909–913.
   PubMed Web of Science ®Google Scholar
• Sinnis P, De La Vega P, Coppi A, et al. Quantification of sporozoite invasion, migration, and development by microscopy and flow cytometry. Methods Mol Biol. 2013;923:385–400.
   PubMedGoogle Scholar
• Cha SJ, Kim MS, Pandey A, et al. Identification of GAPDH on the surface of Plasmodium sporozoites as a new candidate for targeting malaria liver invasion. J Exp Med. 2016;213(10):2099–2112.
   PubMed Web of Science ®Google Scholar
• R. Amino, Giovannini, D., Thiberge, S., et al. Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Cell Host Microbe. 2008;3:88–96.
   PubMed Web of Science ®Google Scholar
• Skardal A, Shupe T, Atala A. Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug Discov Today. 2016;21:1399–1411.
   PubMed Web of Science ®Google Scholar
• H. Azuma, Paulk, N., Ranade, A., et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol. 2007;25:903–910.
   PubMed Web of Science ®Google Scholar
• D. N. Douglas, Kawahara, T., Sis, B., et al. Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease. Plos One. 2010;5:e9209.
   PubMed Web of Science ®Google Scholar
• J. G. Kublin, Mikolajczak, S.A., Sack, B.K., et al. Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci Transl Med. 2017;9:371.
   Web of Science ®Google Scholar
• E. M. Wilson, Bial, J., Tarlow, B., et al. Extensive double humanization of both liver and hematopoiesis in FRGN mice. Stem Cell Res. 2014;13:404–412.
   PubMed Web of Science ®Google Scholar
• W. Wijayalath, Majji, S., Villasante, E.F., et al. Humanized HLA-DR4.RagKO.IL2RgammacKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria. Malar J. 2014;13:386.
   PubMed Web of Science ®Google Scholar
• Schats R, Bijker EM, Van Gemert G-J, et al. Heterologous Protection against Malaria after Immunization with Plasmodium falciparum Sporozoites. Plos One. 2015;10:e0124243.
   PubMed Web of Science ®Google Scholar
• Polhemus ME, Remich SA, Ogutu BR, et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. Plos One. 2009;4:e6465.
   PubMed Web of Science ®Google Scholar
• S. C. T. P. RTS. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. The Lancet. 2015;386:31–45.
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863–1875.
   PubMed Web of Science ®Google Scholar
• Richie TL, Billingsley PF, Sim BKL, et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 2015;33:7452–7461.
   PubMed Web of Science ®Google Scholar
• Keitany GJ, Sack B, Smithers H, et al. Immunization of mice with live-attenuated late liver stage-arresting Plasmodium yoelii parasites generates protective antibody responses to preerythrocytic stages of malaria. Infect Immun. 2014;82:5143–5153.
   PubMed Web of Science ®Google Scholar
• Sack BK, Miller JL, Vaughan AM, et al. Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect Immun. 2014;82:808–817.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Coates EE, Yamshchikov G, et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015;182:289–301.
   PubMed Web of Science ®Google Scholar
• R. M. Lynch, Boritz, E., Coates, E.E., et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7:319ra206.
   PubMed Web of Science ®Google Scholar
• Gautam R, Nishimura Y, Pegu A, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature. 2016;533:105–109.
   PubMed Web of Science ®Google Scholar
• Schoofs T, Klein F, Braunschweig M, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 2016;352:997–1001.
   PubMed Web of Science ®Google Scholar
• Sparrow E, Friede M, Sheikh M, et al. Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Vaccine. 2016;34:5442–5448.
   PubMed Web of Science ®Google Scholar
• E. Arduin, Arora, S., Bamert, P.R., et al. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a. Mol Immunol. 2015;63:456–463.
   PubMed Web of Science ®Google Scholar
• A. J. Hessell, Hangartner, L., Hunter, M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449:101–104.
   PubMed Web of Science ®Google Scholar
• Clemens J, Moorthy V. Implementation of RTS,S/AS01 Malaria Vaccine–The Need for Further Evidence. N Engl J Med. 2016;374:2596–2597.
   PubMed Web of Science ®Google Scholar